PTEN and the PI3-kinase pathway in cancer.

By N. Chalhoub, Suzanne J. Baker. Annual Review of Pathology, 2009

1,241 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1260266ddc9db49a151a31c24e486bb8c72aec03

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Arul M. Chinnaiyan

Citations in the corpus

Principles and Current Strategies for Targeting Autophagy for Cancer Treatment (2011, background): “Although PTEN mutation is generally associated with therapeutic resistance in glioma and other cancers (53), dual inhibitors of PI3K/mTOR when combined with chloroquine readily induce apoptosis of PTEN mutant glioma in vivo.”
ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells (2019, background): “Loss of PTEN expression or mutations in the gene, aswell as dysregulation of thePI3K/AKT signaling pathway, were frequently found in many tumors [216, 217].”
PTEN loss in the continuum of common cancers, rare syndromes and mouse models (2011, neutral): “and PTEN deletion, mutation or alteration occurs in many sporadic tumour”
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal (2014, background): “Mario F. Muñoz was supported by Consejeria de Economı́a, Innovacion y Ciencia de la Junta de Andalucia (Spain) postdoctoral fellowship (P10-CTS-6494).”
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. (2010, background): “Why should this be? As previously mentioned, several recent studies have revealed that upregulation of the PI3K-Akt pathway, which is common in cancer as a result of PTEN inactivation and other mechanisms (Chalhoub and Baker, 2009), inhibits both HRR and checkpoint activation by suppressing DNA dama”
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011, background): “Further, amplification of AR implies intact androgen signaling in the tumor, and loss of PTENsupports a possible role of the PI3K (phosphatidylinositol 3-kinase) pathway (12).”
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011, background): “ Also these pathways can interact with the Wnt/‐catenin pathway which is important in developmental processes, EMT and CICs.”
Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions (2021, background): “Once activated, PI3K subsequently phosphorylates AKT which regulates cell cycle and apoptosis (Chalhoub and Baker, 2009).”
Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Dual PI3K/mTOR inhibitors in advanced clinical trials include NVP-BEZ235 (glioblastomas) [184], XL765 (breast cancer) [185], GDC0980 (mRCC) [186], PF04691502 (breast cancer) [187], GSK2126458 (colorectal, breast, non-small cell lung, and pancreatic cancers) [188], Quinacrine (various leukemias) [189”
Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness (2014, background): “PTEN has been identified as one of the most commonly lost or mutated tumor suppressor genes in human cancers (Chalhoub and Baker, 2009).”